Avita Medical, Inc. Common Stock (RCEL) Stock Price
RCELStock
$13.04+142.38%52W
Market Cap$403.29M
P/E—
PEG Ratio—
Div yield—
Beta2.06
RCEL Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)122.95%
Price vs S&P 500 (4W)21.62%
VGM Score56.72
RCEL Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.39 | -$0.36 | +7.90%(+$0.03) | |
| Q1 2026 | -$0.38 | -$0.48 | -27.34%(-$0.10) | |
| Q4 2025 | -$0.55 | -$0.54 | +2.78%(+$0.02) | |
| Q3 2025 | -$0.46 | -$0.71 | -56.31%(-$0.26) | |
| Q2 2025 | -$0.36 | -$0.58 | -63.49%(-$0.23) |
RCEL Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.09
4.10
3.90
3.90
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
RCELAvita Medical, Inc. Common Stock | D | C | A | 5.3x | 19.6% | 82.1% | -46.6% | $13.04 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Avita Medical, Inc. Common Stock
Avita is a medical device company focused on the RECELL system, a proprietary burn treatment technology that creates Spray-on Skin from small patient samples in approximately 30 minutes, reducing the need for traditional skin grafts. The FDA-approved system is used across most of the nation's 140 burn centers and has expanded indications for soft-tissue reconstruction. While holding approvals in multiple countries, Avita focuses primarily on the US market, though international sales—particularly in Japan—are growing.